{"id":"NCT01371721","sponsor":"Pfizer","briefTitle":"A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD","officialTitle":"A 6 Month, Open Label, Multi Center, Flexible Dose Extension Study To The B2061014 Study To Evaluate The Safety, Tolerability And Efficacy Of Desvenlafaxine Succinate Sustained Release (Dvs Sr) Tablets In The Treatment Of Children And Adolescent Outpatients With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-02","primaryCompletion":"2015-10","completion":"2015-10","firstPosted":"2011-06-13","resultsPosted":"2017-02-08","lastUpdate":"2017-02-08"},"enrollment":269,"design":{"allocation":null,"model":null,"masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"DVS SR","otherNames":[]}],"arms":[{"label":"Desvenlafaxine Succinate Sustained-Release","type":"EXPERIMENTAL"}],"summary":"This is a 6-month, open-label, flexible-dose study evaluating desvenlafaxine succinate sustained release (DVS SR) in the treatment of child and adolescent outpatients with major depressive disorder (MDD).","primaryOutcome":{"measure":"Percentage of Participants Experiencing a Treatment Emergent Adverse Event","timeFrame":"Week 9 (B2061014)/Day 1 (B2061031) to Week 26 of the B2061031 Study","effectByArm":[{"arm":"Placebo / DVS SR","deltaMin":70.1,"sd":null},{"arm":"Fluoxetine / DVS SR","deltaMin":75.3,"sd":null},{"arm":"Desvenlafaxine Succinate Sustained Release / DVS SR","deltaMin":73.9,"sd":null},{"arm":"Combination","deltaMin":73.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":35,"countries":["United States","Mexico"]},"refs":{"pmids":["30419989"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2061031&StudyName=A%206-Month%20Open-Label%20Extension%20Study%20to%20the%20B2061014%20Study%20to%20Evaluate%20the%20Safety%2C%20Tolerability%20and%20Efficacy%20of%20DVS%20SR%20in%20the%20Trea"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":87},"commonTop":["Headache","Nausea","Weight increased","Upper respiratory tract infection","Abdominal pain upper"]}}